Delving into the Latest Updates on GSK-1362885 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1362885, GSK 1362885

Target

PYG

Mechanism

PYG inhibitors(Glycogen phosphorylase inhibitors)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetes Mellitus, Noninsulin-Dependent, 2Diabetes Mellitus, Type 2

Originator Organization

GSK Plc

Active Organization-

Inactive Organization

GSK Plc

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

This study is the second administration of GSK1362885 in humans. GSK1362885 is a novel, potent inhibitor of human glycogen phosphorylase (GP) under development for the treatment of type 2 diabetes mellitus (T2DM). This study will investigate the compound's safety, tolerability, pharmacokinetics, and pharmacodynamics in subjects with Type 2 Diabetes Mellitus.

Start Date13 Aug 2009

Sponsor / Collaborator

GSK Plc

NCT00823940 / CompletedPhase 1

A Single-blind, Randomized, Placebo Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Healthy Normal Subjects.

The study will investigate whether GSK1362885 is safe and well-tolerated when administered to normal healthy subjects. The study will also measure blood levels of the study drug to determine how the body processes the drug (pharmacokinetics) and what effects the drug has on the body (pharmacodynamics).

Start Date13 Jan 2009

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with GSK-1362885

Login to view more data

100 Translational Medicine associated with GSK-1362885

Login to view more data

100 Patents (Medical) associated with GSK-1362885

Login to view more data

100 Deals associated with GSK-1362885

Login to view more data